[1] 中华医学会放射学分会介入学组. 布加综合征介入诊疗规范的专家共识. 中华放射学杂志, 2010, 44: 345-349.
[2] Darwish Murad S, Plessier A, Hernandez·Guerra, et al. Etiology management and outcome ofthe budd-chiari syndrome. Ann Intern Med,2009,151:167-175.
[3] Rajani R,Melin T,Bjornsson E.et al.Budd-Chiari syndrome in Sweden:epidemiology,clinical characteristics and survival an 18 year experience.Liver Int,2009,29:253-259.
[4] Darwish MS, Plessier A, Hernandez-Guerra M. et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med, 2009, 151: 167-175.
[5] Uskudar O, Akdogan M, Sasmaz N, et al. Etiology and portal vein throm-bosis in Budd-chiari syndrome. Word J Genterol, 2008, 14: 2858-2862.
[6] 肖培瑞, 蔺新英, 郭成浩. 布一加综合征地理分布与饮川水碘含量的关系.临床肝胆病杂志, 2011, 27: 130-133.
[7] Muratsu J, Morishima A, Mizoguchi K,et al. Budd-chiari syndrome with multiple thrombi due to a familial arg42Ser mutation in the protein C gene. Case Rep Med, 2013, 2013: 2704-19.
[8] Ramfrez-de-la-Piscina P, Estrada S, Calderon R,et al. Budd-Chiari syndrome secondary to infl ammatory pseudotumor of the liver:report of a case with a 10-year follow-up. Rev Esp Enferm Dig, 2013, 105: 360-362.
[9] Wu JS, Poon WT, Ma CK, et al. Budd-Chiari syndrome secondary to toxic pyrrolizidine alkaloid exposure. Hong Kong Med J, 2013,19: 553-555.
[10] 李胜利, 孙桂香, 祖茂衡. 1994~2007年495例布加综合征流行病学及临床特征分析. 中华疾病控制杂志, 2012, 14: 812-813
[11] Bahar K, Karayalcin S, Kaya M, et al. Percutaneous transhepatic venoplasty an alternative treatment for Budd-chiari syndrome.Turk J Gastroenterol,2002,13:83-88. |
